JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263763

Human MSH6 knockout HeLa cell lysate

5

(1 Review)

|

(0 Publication)

MSH6 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4.

View Alternative Names

DNA mismatch repair protein Msh6, G/T mismatch-binding protein, GTBP, GTMBP, HNPCC 5, HSAP, MSH6_HUMAN, MutS homolog 6 (E. coli), MutS-alpha 160 kDa subunit, Sperm associated protein, hMSH6, mutS (E. coli) homolog 6, mutS homolog 6, p160

3 Images
Western blot - Human MSH6 knockout HeLa cell lysate (AB263763)
  • WB

Lab

Western blot - Human MSH6 knockout HeLa cell lysate (AB263763)

Lane 1 : Wild-type HeLa cell lysate (20µg)

Lane 2 : MSH6 knockout HeLa cell lysate (20µg)

Lanes 1- 2 : Merged signal (red and green). Green - ab14204 observed at 160 kDa. Red - loading control ab52866 observed at 50 kDa.

ab14204 Anti-MSH6 antibody [44] was shown to specifically react with MSH6 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab255410 (knockout cell lysate ab263763) was used. Wild-type and MSH6 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab14204 and Anti-alpha Tubulin antibody [EP1332Y] - Microtubule Marker (ab52866) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-MSH6 antibody [44] (<a href='/en-us/products/primary-antibodies/msh6-antibody-44-ab14204'>ab14204</a>) at 1/500 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

MSH6 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human MSH6 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-msh6-knockout-hela-cell-line-ab255410'>ab255410</a>)

Predicted band size: 153 kDa

Observed band size: 160 kDa

false

Western blot - Human MSH6 knockout HeLa cell lysate (AB263763)
  • WB

Lab

Western blot - Human MSH6 knockout HeLa cell lysate (AB263763)

Lane 1 : Wild-type HeLa cell lysate (20µg)

Lane 2 : MSH6 knockout HeLa cell lysate (20µg)

Lanes 1- 2 : Merged signal (red and green). Green - ab92471 observed at 160 kDa. Red - loading control ab130007 observed at 124 kDa.

ab92471 Recombinant Anti-MSH6 antibody [EPR3945] was shown to specifically react with MSH6 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab255410 (knockout cell lysate ab263763) was used. Wild-type and MSH6 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab92471 and Anti-Vinculin antibody [VIN-54] were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-MSH6 antibody [EPR3945] (<a href='/en-us/products/primary-antibodies/msh6-antibody-epr3945-ab92471'>ab92471</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

MSH6 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human MSH6 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-msh6-knockout-hela-cell-line-ab255410'>ab255410</a>)

Predicted band size: 153 kDa

Observed band size: 160 kDa

false

Sanger Sequencing - Human MSH6 knockout HeLa cell lysate (AB263763)
  • Sanger seq

Unknown

Sanger Sequencing - Human MSH6 knockout HeLa cell lysate (AB263763)

Homozygous : 1 bp insertion in exon 4

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4.

Disease

Adenocarcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab263763-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human MSH6 knockout HeLa cell lysate", "number":"AB263763-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB263763-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
MSH6
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MSH6 also known as MutS Homolog 6 is a DNA repair protein that plays a role in the mismatch repair (MMR) system. It has a molecular mass of approximately 136 kDa. MSH6 forms a heterodimer with MSH2 called MutSα and this complex identifies base-pair mismatches and insertion-deletion loops during DNA replication. It is expressed in various tissues throughout the body and high levels are often found in proliferative tissues where active DNA replication occurs.
Biological function summary

MSH6 functions as part of the MMR complex which is essential for maintaining genomic stability. The MutSα complex where MSH6 pairs with MSH2 operates along with other proteins in the MMR pathway to correct DNA replication errors. MSH6 is also known to interact with PCNA a DNA polymerase processivity factor which facilitates its role in the repair process.

Pathways

MSH6 participates prominently in the DNA mismatch repair pathway. This pathway is critical for correcting DNA errors and preventing mutations during replication. In association with MLH1-PMS2 (MutLα complex) MSH6 ensures that DNA integrity is preserved. Additionally MSH6 is involved in the base excision repair (BER) pathway where it collaborates with other repair proteins to fix small base lesions.

MSH6 has a significant connection with Lynch syndrome also known as hereditary nonpolyposis colorectal cancer (HNPCC). This condition is characterized by germline mutations in MMR genes including MSH6 leading to increased cancer risk particularly in the colon. Moreover alterations in MSH6 can contribute to microsatellite instability a feature seen in certain types of endometrial cancer. Mutations in MSH2 often accompany MSH6 mutations in these disorders further impacting the MMR pathway's efficiency.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB92471

Anti-MSH6 antibody [EPR3945]

BOND RX™ Validated|RabMAb|Recombinant|KO Validated|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MSH6 antibody [EPR3945] (AB92471)

  • 5
  • 5
Proteins & Peptides

AB180317

Recombinant Human POLR1C protein

SDS-PAGE - Recombinant Human POLR1C protein (AB180317)

  • 0
  • 0
Proteins & Peptides

AB259412

Recombinant human VEGF 165A protein (Active)

Premium Bioactive

Mass Spectrometry - Recombinant human VEGF 165A protein (Active) (AB259412)

  • 0
  • 0
Proteins & Peptides

AB52101

Recombinant human Cleaved Caspase-3 protein (Active)

Western blot - Recombinant human Cleaved Caspase-3 protein (Active) (AB52101)

  • 0
  • 0

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com